Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 186 participants.

Also called NCT06962098

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 186 participants (planned count) (from the registry)
Sponsor
Aptabio Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT06962098
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06962098. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Acronym
PROMISS-DKD
Condition
Diabetic Kidney Disease (DKD)
Intervention (Drug)
Isuzinaxib
Intervention (Drug)
Placebo
Lead sponsor
Aptabio Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06962098
Content hash
52beacd42bfca174cae49e7f5d3b40d3949c9b139f7672f5818c6ac70e162abf